A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Lucitanib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology
- 05 Aug 2019 Status changed to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.